Pub Date : 2019-02-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.01.006
Wenbin Xu, H. Xia, Weiying Zheng
Objective To analyze the cancergene expression profile data using multi-support vector machine recursive feature elimination algorithm (MSVM-RFE) and calculate the genetic ranking score to obtain the optimal feature gene subset. Methods Gene expression profiles of bladder cancer, breast cancer, colon cancer and lung cancer were downloaded from GEO (Gene Expression Omnibus) database. The differentially expressed genes were obtained by differential expression analysis. The differential gene expressions were sequenced by MSVM-RFE algorithm and the average test errors of each gene subset were calculated. Then the optimal gene subsetsof four kinds of cancer were obtained according to the minimum average test errors. Based on the datasets of four kinds of cancer characteristic genes before and after screening, linear SVM classifiers were constructed and the classification efficiencies of the optimal feature gene subsets were verified. Results Using the optimal feature gene subsetobtained by MSVM-RFE algorithm, the classification accuracy was improved from (96.77±1.28)% to (99.85±0.46)% for the bladder cancer data, improved from (83.77±4.93)% to (88.30±3.85)% for the breast cancer data, and improved from (72.69±2.41)% to (90.21±3.31)% for the lung cancer data.Besides, theoptimal feature gene subsetkept the classification accuracy of colon cancer classifierat a high level (>99.5%). Conclusions The feature gene extraction based on MSVM-RFE algorithm can improve the classification efficiency of cancer. Key words: Gene expression profile; Recursive feature elimination; Support vector machine; Feature gene
{"title":"Application of multiple support vector machine recursive feature elimination model in cancer feature gene selection","authors":"Wenbin Xu, H. Xia, Weiying Zheng","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.01.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.01.006","url":null,"abstract":"Objective \u0000To analyze the cancergene expression profile data using multi-support vector machine recursive feature elimination algorithm (MSVM-RFE) and calculate the genetic ranking score to obtain the optimal feature gene subset. \u0000 \u0000 \u0000Methods \u0000Gene expression profiles of bladder cancer, breast cancer, colon cancer and lung cancer were downloaded from GEO (Gene Expression Omnibus) database. The differentially expressed genes were obtained by differential expression analysis. The differential gene expressions were sequenced by MSVM-RFE algorithm and the average test errors of each gene subset were calculated. Then the optimal gene subsetsof four kinds of cancer were obtained according to the minimum average test errors. Based on the datasets of four kinds of cancer characteristic genes before and after screening, linear SVM classifiers were constructed and the classification efficiencies of the optimal feature gene subsets were verified. \u0000 \u0000 \u0000Results \u0000Using the optimal feature gene subsetobtained by MSVM-RFE algorithm, the classification accuracy was improved from (96.77±1.28)% to (99.85±0.46)% for the bladder cancer data, improved from (83.77±4.93)% to (88.30±3.85)% for the breast cancer data, and improved from (72.69±2.41)% to (90.21±3.31)% for the lung cancer data.Besides, theoptimal feature gene subsetkept the classification accuracy of colon cancer classifierat a high level (>99.5%). \u0000 \u0000 \u0000Conclusions \u0000The feature gene extraction based on MSVM-RFE algorithm can improve the classification efficiency of cancer. \u0000 \u0000 \u0000Key words: \u0000Gene expression profile; Recursive feature elimination; Support vector machine; Feature gene","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47729389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.01.014
Yunfei Deng, Xiaoxiao Liu, Yanzhuo Zhao
With the development of the next-generation sequencing technology, circular RNAs(circRNAs) are again receiving attention. Circular RNAs have a circular structure that without 5' and a 3' ending. This special structural characteristics and unique formation mechanism (backsplicing) has been known well, but few studies aim to its biological functions. Related researches are mainly focused on its functions as a regulator of the splicing of pre-mRNAs and the expression of parental gene in nucleus or as a competitive inhibitor of miRNAs absorbed by the circRNAs in cytoplasm. The related diseases include Parkinson disease, diabetes, cancers, cardiomyopathy and so on. According to the nature of the sequence contained in the ring, circRNAs can be divided into circular exonic RNA, circular intronic RNA, and ElciRNAs. The sequences contained within the circRNAs are mainly exons, whose ability of guiding the protein synthesis still remains controversial. In this paper, the current researches on the translation ability of circRNAs were reviewed, and the possible biological information tools and lab methods to identify such ability were recommended. Key words: circRNAs; Translation; Identification; Methods
{"title":"Research Progress in the translation ability of circular RNAs","authors":"Yunfei Deng, Xiaoxiao Liu, Yanzhuo Zhao","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.01.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.01.014","url":null,"abstract":"With the development of the next-generation sequencing technology, circular RNAs(circRNAs) are again receiving attention. Circular RNAs have a circular structure that without 5' and a 3' ending. This special structural characteristics and unique formation mechanism (backsplicing) has been known well, but few studies aim to its biological functions. Related researches are mainly focused on its functions as a regulator of the splicing of pre-mRNAs and the expression of parental gene in nucleus or as a competitive inhibitor of miRNAs absorbed by the circRNAs in cytoplasm. The related diseases include Parkinson disease, diabetes, cancers, cardiomyopathy and so on. According to the nature of the sequence contained in the ring, circRNAs can be divided into circular exonic RNA, circular intronic RNA, and ElciRNAs. The sequences contained within the circRNAs are mainly exons, whose ability of guiding the protein synthesis still remains controversial. In this paper, the current researches on the translation ability of circRNAs were reviewed, and the possible biological information tools and lab methods to identify such ability were recommended. \u0000 \u0000 \u0000Key words: \u0000circRNAs; Translation; Identification; Methods","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42927865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.01.016
Dawei Tian
Cisplatin-based chemotherapy is not effective in patients with advanced urothelial carcinoma. Recently, the application of immunological checkpoint inhibitors has brought new insight to resolve this problem. Since May 2016, five drugs, including Atezolizumab, Pembrolizumab, Nivolumab, Avelumab, and Durvalumab, targeting the PD-1/PD-L1 pathway have been approved by the FDA for the treatment of cisplatin-ineligible patients with advanced urothelial carcinoma, of which Pembrolizumab and Atezolizumab are the first-line drugs in the above treatments. The clinical efficacy and safety of these drugs are similar in different trials, but only Pembrolizumab is supported by a current level I evidence from a large randomized phase clinical trials. The results show that in the case of cisplatin ineligibility, Pembrolizumab is more effective than the traditional salvage chemotherapy in overall survival rate. Pembrolizuma is most effective in the treatment of cisplatin-ineligible patients with advanced urothelial carcinoma, while Pembrolizumab and Atezolizumab have similar efficacy in clinical applications of patients with cisplatin ineffective. Key words: Advanced urothelial carcinoma; Immune checkpoint inhibitors; PD-1/PD-L1; Clinical trials
{"title":"Research progress in immunotherapy against PD-1/PD-L1 for advanced urothelial carcinoma","authors":"Dawei Tian","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.01.016","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.01.016","url":null,"abstract":"Cisplatin-based chemotherapy is not effective in patients with advanced urothelial carcinoma. Recently, the application of immunological checkpoint inhibitors has brought new insight to resolve this problem. Since May 2016, five drugs, including Atezolizumab, Pembrolizumab, Nivolumab, Avelumab, and Durvalumab, targeting the PD-1/PD-L1 pathway have been approved by the FDA for the treatment of cisplatin-ineligible patients with advanced urothelial carcinoma, of which Pembrolizumab and Atezolizumab are the first-line drugs in the above treatments. The clinical efficacy and safety of these drugs are similar in different trials, but only Pembrolizumab is supported by a current level I evidence from a large randomized phase clinical trials. The results show that in the case of cisplatin ineligibility, Pembrolizumab is more effective than the traditional salvage chemotherapy in overall survival rate. Pembrolizuma is most effective in the treatment of cisplatin-ineligible patients with advanced urothelial carcinoma, while Pembrolizumab and Atezolizumab have similar efficacy in clinical applications of patients with cisplatin ineffective. \u0000 \u0000 \u0000Key words: \u0000Advanced urothelial carcinoma; Immune checkpoint inhibitors; PD-1/PD-L1; Clinical trials","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43169484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.01.015
Biao Wang
With the gradual integration of molecules, cells and micro tissues, organ models into microfluidic chips, the platform value of microfluidic chips is increasingly prominent in biomedical field. The development of cryopreservation of cell samples on chip is not only the essential condition for realizing this value, but a beneficial innovation for traditional cryopreservation of cell samples. In this paper, the cryopreservation techniques of cell samples on microfluidic chips were reviewed, including slow freezing of cell samples on chips and temperature control in this process, theoretical analysis and verification of vitrification of cell samples on chips. Furthermore, preservation of cell samples on chips at non-cryogenic temperature was introduced. Finally, the dynamics and problems in on-chip cryopreservation of cell samples were briefly analyzed to provide reference for relative researches. Key words: Cryopreservation; Microfluidic chips; Cell samples
{"title":"Research progress in on-chip cryopreservation of living cells","authors":"Biao Wang","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.01.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.01.015","url":null,"abstract":"With the gradual integration of molecules, cells and micro tissues, organ models into microfluidic chips, the platform value of microfluidic chips is increasingly prominent in biomedical field. The development of cryopreservation of cell samples on chip is not only the essential condition for realizing this value, but a beneficial innovation for traditional cryopreservation of cell samples. In this paper, the cryopreservation techniques of cell samples on microfluidic chips were reviewed, including slow freezing of cell samples on chips and temperature control in this process, theoretical analysis and verification of vitrification of cell samples on chips. Furthermore, preservation of cell samples on chips at non-cryogenic temperature was introduced. Finally, the dynamics and problems in on-chip cryopreservation of cell samples were briefly analyzed to provide reference for relative researches. \u0000 \u0000 \u0000Key words: \u0000Cryopreservation; Microfluidic chips; Cell samples","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48680076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.01.013
Dayong Liu
Pulpal and periapical diseases are the common diseases in human diseases. The traditional treatment method for these diseases is root canal treatment, which is to completely remove and control infection, repair or prevent periapical lesions by root canal mechanical preparation, chemical disinfection and filling. At present, although root canal treatments have a high success rate, there are still a series of problems. Dental pulp regeneration has attracted more and more attention from researchers in promoting the formation of pulp-like tissue in root canals. The ultimate goal of regenerative endodontics is to form a functional endodontic-dentin complex with inner blood vessels and nerves, outer layers of dentin cells arranged along the root canal wall, and new dentin formed by secreting matrix, so as to restore pulp vitality. Stem cells, scaffolds, biosignal molecules, and regenerative microenvironment are key tissue engineering factors that affect pulp regeneration. In this paper, the strategies and applications of pulp regeneration were reviewed around the above factors and clinical procedures. Key words: Pulp tissue regeneration; Pulp revascularization; Tissue engineering; Cell transplantation; Cells homing; Scaffolds; Microenviroment
{"title":"Research progress in pulp tissue regeneration strategy in microenvironment","authors":"Dayong Liu","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.01.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.01.013","url":null,"abstract":"Pulpal and periapical diseases are the common diseases in human diseases. The traditional treatment method for these diseases is root canal treatment, which is to completely remove and control infection, repair or prevent periapical lesions by root canal mechanical preparation, chemical disinfection and filling. At present, although root canal treatments have a high success rate, there are still a series of problems. Dental pulp regeneration has attracted more and more attention from researchers in promoting the formation of pulp-like tissue in root canals. The ultimate goal of regenerative endodontics is to form a functional endodontic-dentin complex with inner blood vessels and nerves, outer layers of dentin cells arranged along the root canal wall, and new dentin formed by secreting matrix, so as to restore pulp vitality. Stem cells, scaffolds, biosignal molecules, and regenerative microenvironment are key tissue engineering factors that affect pulp regeneration. In this paper, the strategies and applications of pulp regeneration were reviewed around the above factors and clinical procedures. \u0000 \u0000 \u0000Key words: \u0000Pulp tissue regeneration; Pulp revascularization; Tissue engineering; Cell transplantation; Cells homing; Scaffolds; Microenviroment","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48184394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.01.008
Yue Han, L. Ning, Xiaolong Zong, Dianjun Wei
Objective To detect the expression levels of insulin-like growth factor 1 (IGF-1) and leptin (LP) in serum of patients with colorectal cancer, and to analyze its clinical significance. Methods Seventy-three patients with colorectal cancer, 37 patients with benign colorectal cancer and 40 healthy subjects were enrolled. Serum IGF-1 and LP levels of all the subjects were measured. A two-year follow-up study of colorectal patients was performed to observe the occurrence of lymph node metastasis. Logistic regression was used to analyze the factors affecting lymph node metastasis in colorectal cancer patients. The area under the receiver operating characteristic curve (AUC) was used to analyze the diagnostic value of IGF-1 and LP for colorectal cancer and recurrence. Results The serum IGF-1 concentration in colorectal cancer was significantly lower than that in the control group (P 0.05). The serum LP level of colorectal cancer was significantly higher than that of benign lesions and control group (P<0.05). Both IGF-1 and LP have certain diagnostic value for colorectal cancer, and the combined test and efficacy of the two methods are higher than those of the separate test (P<0.05). The two-year recurrence rate of colorectal cancer patients was 16.43%, and the patient age (≥40 years old), TNM grade (Ⅲ~Ⅳ grade), tumor diameter (≥4 cm), vascular infiltration and deep muscle infiltration in the recurrent patients were significantly higher than that in the untreated patients (all P<0.05). In the cancer metastasis patients, the level of serum IGF-1 and LP was significantly lower and higher than that in non-metastatic patients, respectively (all P<0.05). Vascular infiltration, deep myometrial invasion, low IGF-1 levels, and high LP levels were independent predictors of recurrence in colorectal cancer patients, and the combined predictive AUC of the above four factors was 0.956 (95%CI: 0.988 1~0.990). Conclusions In patients with colorectal cancer, IGF-1 level is low and LP level is high, which is closely related to cancer recurrence. Key words: Insulin-like growth factor; Leptin; Colorectal cancer; Risk factors; Diagnosis
{"title":"Expression and clinical significance of IGF-1 and LP in serum of colorectal cancer patients","authors":"Yue Han, L. Ning, Xiaolong Zong, Dianjun Wei","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.01.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.01.008","url":null,"abstract":"Objective \u0000To detect the expression levels of insulin-like growth factor 1 (IGF-1) and leptin (LP) in serum of patients with colorectal cancer, and to analyze its clinical significance. \u0000 \u0000 \u0000Methods \u0000Seventy-three patients with colorectal cancer, 37 patients with benign colorectal cancer and 40 healthy subjects were enrolled. Serum IGF-1 and LP levels of all the subjects were measured. A two-year follow-up study of colorectal patients was performed to observe the occurrence of lymph node metastasis. Logistic regression was used to analyze the factors affecting lymph node metastasis in colorectal cancer patients. The area under the receiver operating characteristic curve (AUC) was used to analyze the diagnostic value of IGF-1 and LP for colorectal cancer and recurrence. \u0000 \u0000 \u0000Results \u0000The serum IGF-1 concentration in colorectal cancer was significantly lower than that in the control group (P 0.05). The serum LP level of colorectal cancer was significantly higher than that of benign lesions and control group (P<0.05). Both IGF-1 and LP have certain diagnostic value for colorectal cancer, and the combined test and efficacy of the two methods are higher than those of the separate test (P<0.05). The two-year recurrence rate of colorectal cancer patients was 16.43%, and the patient age (≥40 years old), TNM grade (Ⅲ~Ⅳ grade), tumor diameter (≥4 cm), vascular infiltration and deep muscle infiltration in the recurrent patients were significantly higher than that in the untreated patients (all P<0.05). In the cancer metastasis patients, the level of serum IGF-1 and LP was significantly lower and higher than that in non-metastatic patients, respectively (all P<0.05). Vascular infiltration, deep myometrial invasion, low IGF-1 levels, and high LP levels were independent predictors of recurrence in colorectal cancer patients, and the combined predictive AUC of the above four factors was 0.956 (95%CI: 0.988 1~0.990). \u0000 \u0000 \u0000Conclusions \u0000In patients with colorectal cancer, IGF-1 level is low and LP level is high, which is closely related to cancer recurrence. \u0000 \u0000 \u0000Key words: \u0000Insulin-like growth factor; Leptin; Colorectal cancer; Risk factors; Diagnosis","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69894511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective To compare the dosimetric characteristics of the methods of volumetric modulated arc therapy (VMAT) for craniospinal irradiation, and to compare their robustness to the field placement error. Methods Six patients receiving craniospinal irradiation were included. VMAT plans of each patient were optimized with overlap method and gradient-optimization method respectively using Pinnacle 9.8 VMAT treatment planning system. The length of the overlap region was set as 3 and 9 cm, respectively. Then the dose distributions under different VMAT programs were measured. Moreover, a 3 mm placement error was introduced, and the dose cold spot in the field junction region obtained by each plan was compared for robustness analysis. Results Under different overlapping lengths, the overlap method and the gradient optimization method both can optimize the VMAT plan that meeting the clinical requirements. In the field junction region, the dose distribution obtained by the overlap method was more uniform, and the difference in the uniformity index was statistically significant. When introducing a 3 mm placement error, the gradient optimization method obtained the most robust VMAT plan at 9 cm overlap length, and the overlap method could not obtained stabilized robust plan. Conclusions For the optimization of craniospinal irradiation VMAT plan, the commonly used overlap method can obtain a better dose distribution, but it can't improve robustness by increasing overlap length. However, using the gradient optimization method, the dose homogeneity in the field junction region is not good as the overlap method, but the plan robustness can be improved by increasing the overlap length. Key words: Craniospinal irradiation; Volumetric modulated arc therapy; Robustness; Overlap gradient-optimization
{"title":"Plan robustness of craniospinal irradiation with VMAT","authors":"Jian Xu, Qiang Wang, Keqiang Wang, Huipeng Meng, Hua-jiang Dong","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.01.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.01.009","url":null,"abstract":"Objective \u0000To compare the dosimetric characteristics of the methods of volumetric modulated arc therapy (VMAT) for craniospinal irradiation, and to compare their robustness to the field placement error. \u0000 \u0000 \u0000Methods \u0000Six patients receiving craniospinal irradiation were included. VMAT plans of each patient were optimized with overlap method and gradient-optimization method respectively using Pinnacle 9.8 VMAT treatment planning system. The length of the overlap region was set as 3 and 9 cm, respectively. Then the dose distributions under different VMAT programs were measured. Moreover, a 3 mm placement error was introduced, and the dose cold spot in the field junction region obtained by each plan was compared for robustness analysis. \u0000 \u0000 \u0000Results \u0000Under different overlapping lengths, the overlap method and the gradient optimization method both can optimize the VMAT plan that meeting the clinical requirements. In the field junction region, the dose distribution obtained by the overlap method was more uniform, and the difference in the uniformity index was statistically significant. When introducing a 3 mm placement error, the gradient optimization method obtained the most robust VMAT plan at 9 cm overlap length, and the overlap method could not obtained stabilized robust plan. \u0000 \u0000 \u0000Conclusions \u0000For the optimization of craniospinal irradiation VMAT plan, the commonly used overlap method can obtain a better dose distribution, but it can't improve robustness by increasing overlap length. However, using the gradient optimization method, the dose homogeneity in the field junction region is not good as the overlap method, but the plan robustness can be improved by increasing the overlap length. \u0000 \u0000 \u0000Key words: \u0000Craniospinal irradiation; Volumetric modulated arc therapy; Robustness; Overlap gradient-optimization","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69894574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.01.003
Yintao Ye, W. Zhong, Junqiang Qian, Yun-Wei Shi, Chen Wang
Objective To investigate the effect of L-carnitine (LCNT) combined with epirubicin (EPI) on cell proliferation and apoptosis of two lung adenocarcinoma cell lines (GLC-82 and A549). Methods GLC-82 and A549 cells were divided into control group, EPI group, LCNT group and EPI+LCNT group, respectively. The cell proliferation rate was examined by MTT assay 24 h after the treatment, and the cell cycle and cell early apoptosis were analyzed by flow cytometry. The expression of P53 and Bcl-2 proteins were detected by Western Blot. Results Compared with the control group, the proliferation rate of GLC-82 and A549 cells was 37.56%(P 0.05) after 24 hours of 20.00 μg/ml LCNT treatment indicating LCNT could promote the proliferation of GLC-82 cells. Compared with the EPI group, EPI+LCNT had smaller inhibitory effect on the proliferation of GLC-82 cells, and the inhibition rate of the EPI+LCNT group was 12.14% lower than that of EPI group (P 0.05). Conclusions Comparing with the EPI, the combination of LCNT and EPI has less proliferation inhibition and apoptosis induction on GLC-82 cells, and without significant effect on A549 cells. LCNT can promote the proliferation of GLC-82 cells and block the cell cycle at G0/G1 phase. This mechanism may be related to down-regulation of P53 protein and up-regulation of Bcl-2 protein expression. Key words: Lung neoplasms; Adenocarcinoma; Cell proliferation; Cell apoptosis; L-carnitine; Epirubicin
{"title":"Effects of cell proliferation and apoptosis of L-carnitine combined with epirubicin on different human lung adenocarcinoma cells","authors":"Yintao Ye, W. Zhong, Junqiang Qian, Yun-Wei Shi, Chen Wang","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.01.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.01.003","url":null,"abstract":"Objective \u0000To investigate the effect of L-carnitine (LCNT) combined with epirubicin (EPI) on cell proliferation and apoptosis of two lung adenocarcinoma cell lines (GLC-82 and A549). \u0000 \u0000 \u0000Methods \u0000GLC-82 and A549 cells were divided into control group, EPI group, LCNT group and EPI+LCNT group, respectively. The cell proliferation rate was examined by MTT assay 24 h after the treatment, and the cell cycle and cell early apoptosis were analyzed by flow cytometry. The expression of P53 and Bcl-2 proteins were detected by Western Blot. \u0000 \u0000 \u0000Results \u0000Compared with the control group, the proliferation rate of GLC-82 and A549 cells was 37.56%(P 0.05) after 24 hours of 20.00 μg/ml LCNT treatment indicating LCNT could promote the proliferation of GLC-82 cells. Compared with the EPI group, EPI+LCNT had smaller inhibitory effect on the proliferation of GLC-82 cells, and the inhibition rate of the EPI+LCNT group was 12.14% lower than that of EPI group (P 0.05). \u0000 \u0000 \u0000Conclusions \u0000Comparing with the EPI, the combination of LCNT and EPI has less proliferation inhibition and apoptosis induction on GLC-82 cells, and without significant effect on A549 cells. LCNT can promote the proliferation of GLC-82 cells and block the cell cycle at G0/G1 phase. This mechanism may be related to down-regulation of P53 protein and up-regulation of Bcl-2 protein expression. \u0000 \u0000 \u0000Key words: \u0000Lung neoplasms; Adenocarcinoma; Cell proliferation; Cell apoptosis; L-carnitine; Epirubicin","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49385339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.01.005
Jing-peng Hao, S. Dong, B. He, Mei Han, Menglong Li, Penghao Li, B. Zheng
Objective To investigate the mechanism of MDM2-p53 signaling pathway in the development of colorectal cancer and correlation between p53 with clinicopathological parameters, so as to further analyze the effect of p53 on prognosis. Methods The colorectal cancer tissues and the adjacent normal tissues from 86 cases of patients with colorectal cancer were collected. The expression of p53 and murine double minute 2(MDM2) in colorectal cancer and adjacent normal tissues were detected by immunohistochemistry, Western Blot and real-time fluorescence quantitative polymerase chain reaction (RT-PCR). The prognosis of the patients was analyzed by the Kaplan-Meier survival curves. Results The protein expression and the mRNA expression of p53 and MDM2 in colorectal cancer tissues were significantly higher than that in the adjacent non-cancerous tissues (all P<0.01). A positive correlation was observed between the expression of p53 and MDM2 (r=0.785). The expression of p53 in colorectal cancer tissues were correlated well with the degree of tumor differentiation, TNM stage, lymph node metastasis and infiltration depth (all P<0.05). Survival analysis demonstrated that the mean overall survival time in p53 high expression group was (53.92±1.56) months which was significantly lower than that in p53 low expression group of (69.16±3.72) months, and the difference was statistically significant (χ2=14.78, P<0.01). Conclusions The risk and prognosis of colorectal cancer are closely related to the MDM2-p53 signaling pathway. p53 can be used as a potential target for the prognosis and treatment of colorectal cancer. Key words: Colorectal cancer; p53; Murine double minute 2; Clinicopathological features; Signaling pathway; Prognosis
{"title":"Role of MDM2-p53 signaling pathway in the development of colorectal cancer","authors":"Jing-peng Hao, S. Dong, B. He, Mei Han, Menglong Li, Penghao Li, B. Zheng","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.01.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.01.005","url":null,"abstract":"Objective \u0000To investigate the mechanism of MDM2-p53 signaling pathway in the development of colorectal cancer and correlation between p53 with clinicopathological parameters, so as to further analyze the effect of p53 on prognosis. \u0000 \u0000 \u0000Methods \u0000The colorectal cancer tissues and the adjacent normal tissues from 86 cases of patients with colorectal cancer were collected. The expression of p53 and murine double minute 2(MDM2) in colorectal cancer and adjacent normal tissues were detected by immunohistochemistry, Western Blot and real-time fluorescence quantitative polymerase chain reaction (RT-PCR). The prognosis of the patients was analyzed by the Kaplan-Meier survival curves. \u0000 \u0000 \u0000Results \u0000The protein expression and the mRNA expression of p53 and MDM2 in colorectal cancer tissues were significantly higher than that in the adjacent non-cancerous tissues (all P<0.01). A positive correlation was observed between the expression of p53 and MDM2 (r=0.785). The expression of p53 in colorectal cancer tissues were correlated well with the degree of tumor differentiation, TNM stage, lymph node metastasis and infiltration depth (all P<0.05). Survival analysis demonstrated that the mean overall survival time in p53 high expression group was (53.92±1.56) months which was significantly lower than that in p53 low expression group of (69.16±3.72) months, and the difference was statistically significant (χ2=14.78, P<0.01). \u0000 \u0000 \u0000Conclusions \u0000The risk and prognosis of colorectal cancer are closely related to the MDM2-p53 signaling pathway. p53 can be used as a potential target for the prognosis and treatment of colorectal cancer. \u0000 \u0000 \u0000Key words: \u0000Colorectal cancer; p53; Murine double minute 2; Clinicopathological features; Signaling pathway; Prognosis","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45264726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.01.012
Chenlu Huang, Dunwan Zhu
In recent years, mesoporous silica nanoparticles (MSNs) have been widely used in the construction of various intelligent drug delivery systems due to their unique and excellent properties. The stimuli-responsive drug delivery system based on mesoporous silica nanoparticles can effectively load anticancer drugs and target them to tumor cells, and then responsively release anticancer drugs under the action of specific stimulation signals. The method of specifically delivering anticancer drugs to target sites not only can greatly improvethe drug efficacy, but also effectively reduce the side effects of anticancer drugs on normal tissues and organs. Thereby the advantages of anticancer drugs in tumor therapy are improved. In this paper, the applications and developments of stimuli-responsive mesoporous silica nano drug delivery systems in tumor therapy were summarized. Key words: Mesoporous silica nanoparticles; Stimuli-responsive; Controlled release; Tumor therapy
{"title":"Research progress in stimuli-responsive mesoporous silica nano drug delivery systems for tumor therapy","authors":"Chenlu Huang, Dunwan Zhu","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.01.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.01.012","url":null,"abstract":"In recent years, mesoporous silica nanoparticles (MSNs) have been widely used in the construction of various intelligent drug delivery systems due to their unique and excellent properties. The stimuli-responsive drug delivery system based on mesoporous silica nanoparticles can effectively load anticancer drugs and target them to tumor cells, and then responsively release anticancer drugs under the action of specific stimulation signals. The method of specifically delivering anticancer drugs to target sites not only can greatly improvethe drug efficacy, but also effectively reduce the side effects of anticancer drugs on normal tissues and organs. Thereby the advantages of anticancer drugs in tumor therapy are improved. In this paper, the applications and developments of stimuli-responsive mesoporous silica nano drug delivery systems in tumor therapy were summarized. \u0000 \u0000 \u0000Key words: \u0000Mesoporous silica nanoparticles; Stimuli-responsive; Controlled release; Tumor therapy","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46374809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：